Sentrx, a leading provider of drug safety services, issued a press release noting that the company doubled the number of biopharmaceutical companies it serves. The company handles data concerning 30,000 adverse events annually. Its technology toolbox includes web-based ways to manage drug safety.

Sentrx began offering adverse event case processing in 1999. It supplies both clinical trial safety monitoring and post-marketing safety surveillance. 

As evidence of satisfied clients, Sentrx noted that four customers renewed contracts for three-year terms. In the case of one sponsor, Sentrx said it has provided clinical trial safety, post-marketing safety surveillance, and safety system hosting for more than six years. During that time, data migration and MedDRA version upgrades were performed as needed, and the capability for electronic submissions was added. Other recent contract renewals represent companies that have been clients for up to four years.

According to the news release: other Sentrx highlights for 2006 include:

•Eleven new multi-year contracts gained

•MedDRA version management automated for hosted clients

As attractive as Sentrx might be as an acquisition target, it appears to be more interested in internal growth. Earlier in the year, the company announced a capital investment by Argosy Partners. Sentrx has also had several rounds of funding from the Edison Venture Fund, which has life science investments in such firms as Taratec, Octagon Research Solutions, Factpoint, Cadient and CambridgeSoft.